Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial.
Melody A CobleighStewart J AndersonKalliopi P SiziopikouDouglas W ArthurRachel RabinovitchThomas B JulianDavid S PardaSamantha A SeawardDennis L CarterJanice A LyonsMelissa S DillmonGustav C MagrinatVivek S KavadiAllison M ZibelliLavanya TiriveedhiMatthew L HillMarianne K MelnikSushil BeriwalEleftherios P P MamounasNorman WolmarkPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Addition of T to RT did not achieve the objective of 36% reduction in IBTR rate but did achieve a modest but statistically nonsignificant reduction of 19%. Nonetheless, this trial had negative results. Further exploration of RT plus T is needed in HER2-positive DCIS before its routine delivery in patients with DCIS resected by lumpectomy.